← Back to patent-cliff list
SX-682
Tier C — Watch / tradeSX-682
Syntrix Biosystems Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CXCR1, CXCR2
Indications (approved)：Nasopharyngeal carcinoma, 副鼻窦肿瘤, 喉肿瘤, Oral squamous cell carcinoma, 口咽部鳞状细胞癌, Prostate cancer, Castration-resistant prostate cancer, Head and neck cancer
Regional status
US
Phase II
2020-10-14
EU
Phase II
2025-04-28
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SX-682?
Approved indications include: Nasopharyngeal carcinoma, 副鼻窦肿瘤, 喉肿瘤, Oral squamous cell carcinoma, 口咽部鳞状细胞癌, Prostate cancer, Castration-resistant prostate cancer, Head and neck cancer.
When does the SX-682 patent expire?
No public expiry year is available for SX-682 yet; this page updates once verified.
How do I get a quote for SX-682 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06